HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy
CompletedOBSERVATIONAL
Enrollment
135
Participants
Timeline
Start Date
June 14, 2013
Primary Completion Date
November 25, 2020
Study Completion Date
November 25, 2020
Conditions
Breast Cancer
Trial Locations (1)
60431
AGAPLESION Markus-Krankenhaus, Frankfurt
All Listed Sponsors
lead
Hoffmann-La Roche
INDUSTRY
NCT01777958 - HELENA Study: An Observational Study of Perjeta (Pertuzumab) in First-Line Treatment in Patients With Her2-Positive Advanced Breast Cancer After Adjuvant Herceptin Therapy | Biotech Hunter | Biotech Hunter